Skip to main content

Healthy Volunteers

Effects of CSL324 in the Lung After Segmental Challenge
NCT05653713 | Phase 1 | Interventional

This is a phase 1b, randomized, double-blind, placebo-controlled study in healthy volunteers to investigate the antiinflammatory effect of pretreatment with CSL324 on response to a lipopolysaccharide (LPS) endotoxin challenge in a single lung segment. Saline will be instilled into a segment in the contralateral lung for the purpose of comparison.

Trial Information
1 Sites
40 Participants
18 Years to 65 Years

If interested, contact for more information

Fraunhofer Institute for Toxicology and Experimental Medicine

Study Eligibility Criteria

  • Male or female volunteer.
  • Between the ages of ≥ 18 and ≤ 65 years.
  • Body mass index within the range of 18 to 32 kg/m2
  • Female of nonchildbearing potential or of childbearing potential and willing to use a highly effective method of contraception (in addition to male partner condom with or without spermicide)
  • Nonsmoker or an ex-smoker who has stopped smoking (including e-cigarettes or vaping devices) for > 1 year with a smoking history of < 10 pack-years.
  • Any clinically significant abnormalities in physical examination findings, electrocardiogram (ECG) readings, safety laboratory test results, or ANC < 2.0 × 109 cells/L.
  • History of myeloproliferative or lymphoproliferative disease.
  • Current or previous history of any immunosuppressive condition.
  • Currently receiving any immunosuppressive or immunomodulatory therapy, or history of undergoing such therapy.

Additional Studies

Additional studies can be found at